TAKEDA PHARMACEUTICALS INTERNATIONAL AG

ADTIEXZO

Pharmaceutical preparations for use in oncology;

ADZYNMA

Pharmaceutical preparations, namely, enzyme replacement therapy for thrombotic disorders;

BEYREZA

Pharmaceutical products for use in the field of neuroscience, namely, for the treatment of neurological and nervous system diseases and disorders; pharmaceutical preparations for the treatment of seizures associated with Dravet Syndrome and Lennox-Gastaut Syndrome;

BEYRIZO

Pharmaceutical products for use in the field of neuroscience, namely, for the treatment of neurological and nervous system diseases and disorders; pharmaceutical preparations for the treatment of seizures associated with Dravet Syndrome and Lennox-Gastaut Syndrome;

BYLTORO

Pharmaceutical preparations for use in oncology;

COVIG-19

Pharmaceutical preparations for the treatment and immunization of coronavirus diseases; blood for medical purposes; blood components for medical purposes, in particular blood plasma;Blood bank services; medical services and paramedical services, namely, collection of blood, and providing transfusions of blood and blood components;Scientific research services in the field of pharmaceuticals related to the treatment and immunization of coronavirus diseases; blood analysis services;

COVIG-19 PLASMA ALLIANCE

Pharmaceutical preparations for the treatment and immunization of coronavirus diseases; blood for medical purposes; blood components for medical purposes, in particular blood plasma;Blood bank services; medical services and paramedical services, namely, collection of blood, and providing transfusions of blood and blood components;PLASMA ALLIANCE;Scientific research services in the field of pharmaceuticals related to the treatment and immunization of coronavirus diseases; blood analysis services;

EXKIVITY

Pharmaceutical preparations for use in oncology;

KOGTHERO

Pharmaceutical preparations for the treatment of enzyme deficiencies; pharmaceutical preparations for the treatment of Hunter's syndrome;

LIVTENCITY

Pharmaceutical preparations for the treatment of infectious diseases;

MOBALRY

Pharmaceutical preparations for the treatment of the consequences of genetic disorders;

MOBLIVGO

Pharmaceutical preparations for the treatment of the consequences of genetic disorders;

MYADMIA

Pharmaceutical preparations, namely, enzyme replacement therapy for thrombotic disorders;

MYAMDIA

Pharmaceutical preparations, namely, enzyme replacement therapy for thrombotic disorders;

SHIRE

pharmaceutical preparations for the treatment of central nervous system disorders, attention deficit/hyperactivity disorders, [ cardiovascular disorders, ] blood disorders, [ cancer, ] gastroenterological disorders, metabolic diseases, [ orthostatic hypotension, ] moderate to moderately severe pain [, and nausea ];[ providing laboratory services in connection with pharmaceutical preparations for treatment of human illnesses developed by applicant or its affiliates ];

SHIRE

The drawing is amended to appear as follows: PUBLISH CUT.;FULL LINE OF PHARMACEUTICAL AND MEDICINAL PREPARATIONS AND SUBSTANCES;SHIRE;[ (( LABORATORY SERVICES IN THE FIELD OF PHARMACOLOGY )) ];

SHIRE

The mark consists of the word SHIRE appearing with a curved line beginning to the left and bottom of the letter S crossing upward and to the right intersecting the top of the letter S.;Color is not claimed as a feature of the mark.;Providing medical information in the field of pharmaceutical products and services;